Abstract
The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells (‘super mobilizers’) have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkin's lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD34+ cells/kg. Two hundred and three patients were super mobilizers, while 147 collected between 2.0 and 7.95 CD34+ cells/kg. Super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens (80 versus 63%, P<0.001). Median CD34+ cell dose for the super mobilizing group was 13.7 × 106 versus 4.4 × 106/kg in the standard collecting group. The super mobilizer group had a superior overall survival (P=0.006). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival. We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bolwell BJ . Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 2003; 32: 853–861.
Copelan EA . Hematopoietic stem cell transplantation. New Engl J Med 2006; 354: 1813–1826.
Bolwell BJ . Factors predicting success or failure associated with common types of transplants. Pediatr Transplant 2005; 9: 2–11.
Gluckman E, Rocha V, Arcese W, Michel G, Sanz G, Chan K et al. Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Exp Hematol 2004; 32: 397–407.
Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.
Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291–298.
Dean R, Masci P, Pohlman B, Andresen S, Serafino S, Sobecks R et al. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant 2005; 36: 1049–1052.
Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Panza SL, Bechtel TP et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759–765.
Kanfer EJ, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley JF et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer 1998; 78: 928–932.
Bolwell BJ, Goormastic M, Yanssens T, Dannley R, Baucco P, Fishleder A . Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913–918.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.
Boeve S, Strupeck J, Creech S, Stiff PJ . Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997–1003.
Ford CD, Green W, Warenski S, Petersen FB . Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901–905.
Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S et al. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant 2004; 34: 85–87.
Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307–1318.
Devine SM, Flomenberg N, Vesole DF, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bolwell, B., Pohlman, B., Rybicki, L. et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 40, 437–441 (2007). https://doi.org/10.1038/sj.bmt.1705763
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705763
Keywords
This article is cited by
-
Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation
Annals of Hematology (2024)
-
Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study
Drugs - Real World Outcomes (2022)
-
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg
Bone Marrow Transplantation (2019)
-
Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis
Current Treatment Options in Neurology (2019)
-
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Nature Reviews Neurology (2017)